Inhibitors of neuropeptide peptidases engaged in pain and drug dependence

Neuropharmacology. 2020 Sep 15:175:108137. doi: 10.1016/j.neuropharm.2020.108137. Epub 2020 Jun 9.

Abstract

Owing to a broad spectrum of functions performed by neuropeptides, this class of signaling molecules attracts an increasing interest. One of the key steps in the regulation of biological activity of neuropeptides is proteolytic conversion or degradation by proteinases that change or terminate biological activity of native peptides. These enzymes, in turn, are regulated by inhibitors, which play integral role in controlling many metabolic pathways. Thus, the search for selective inhibitors and detailed knowledge on the mechanisms of binding of these substances to enzymes, could be of importance for designing new pharmacological approaches. The aim of this review is to summarize the current knowledge on the inhibitors of enzymes that convert selected groups of neuropeptides, such as dynorphins, enkephalins, substance P and NPFF fragments. The importance of these substances in pathophysiological processes involved in pain and drug addiction, have been discussed. This article is part of the special issue on Neuropeptides.

Keywords: Dynorphins; Enkephalins; Inhibitors; Insulin degrading enzyme (IDE); Neuropeptides; Substance P (SP).

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Dynorphins / metabolism
  • Enkephalin, Leucine / metabolism
  • Enzyme Inhibitors / administration & dosage*
  • Humans
  • Neuropeptides / metabolism*
  • Pain / drug therapy*
  • Pain / metabolism
  • Peptide Hydrolases / metabolism*
  • Protease Inhibitors / administration & dosage*
  • Substance-Related Disorders / prevention & control*

Substances

  • Enzyme Inhibitors
  • Neuropeptides
  • Protease Inhibitors
  • Enkephalin, Leucine
  • Dynorphins
  • Peptide Hydrolases